Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody drug aims to tackle stubborn high blood pressure

NCT ID NCT06833190

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called REGN5381 in 34 adults with uncontrolled hypertension (high blood pressure despite taking one or more blood pressure medications). The drug is a monoclonal antibody designed to activate NPR1 receptors, which may help lower blood pressure. The trial was a Phase 2b, randomized, double-blind, placebo-controlled study, but it was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REGN5381 (a monoclonal antibody that targets NPR1 receptors to help lower blood pressure)
What this could lead to
If it works, this could offer a new treatment option for people whose high blood pressure is not controlled by current medications.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

34 people

The number who actually took part.

Started

Apr 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Adults with SBP ≥130 mm Hg and SBP ≤180 mm Hg at both screening and randomization visit, as described in the protocol 2. ≥ 40 and ≤85 years on a stable regimen of ≥1 anti-hypertensive therapy for at least 1 month at the time of screening or ≥30 and \<40 years on a stable regimen of ≥3 anti-hypertensive therapies for at least 1 month at the time of screening Key Exclusion Criteria 1. Heart rate \>100 bpm as described in the protocol 2. Body mass index \>45 kg/m2 as described in the protocol 3. Glomerular filtration rate (GFR) \<30 mL/min/1.73m2 at screening as described in the protocol 4. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≥3x upper limit of normal (ULN) as described in the protocol NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uncontrolled hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uncontrolled hypertension

Contacts and locations

Locations

  • Protas, Car Park of Asda Huyton Supercentre

    Huyton, Liverpool, L36 7TX, United Kingdom

  • Protas, Car Park of Asda Pilsworth Road

    Bury, BL9 8RS, United Kingdom

  • Protas, Two New Bailey Square

    Salford, Manchester, M3 5GS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.